Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!

Related Content

GSK Enters $2.2 Billion Definitive Agreement to Acquire RAPT Therapeutics

ByNicholas Jacobus

January 20th 2026

Pharmaceutical Executive Daily: Henlius' Exclusive License Agreement with U-Mab Biopharma

ByNicholas Jacobus

January 19th 2026

Atkins Announces Partnership with Reality TV Star Heather Gay to Address GLP-1 User’s Mindsets

ByNicholas Jacobus

January 19th 2026

JP Morgan 2026 Wrap Up: Pharma Leaders Speak About the Conference and the State of the Industry

ByMike Hollan

January 19th 2026

Henlius Enters Global Exclusive License Agreement with U-mab Biopharma for Best-in-Class Potential Anti-IL-1RAP mAb

ByNicholas Jacobus

January 19th 2026

June TOC

Newsletter

Related Content

GSK Enters $2.2 Billion Definitive Agreement to Acquire RAPT Therapeutics

Pharmaceutical Executive Daily: Henlius' Exclusive License Agreement with U-Mab Biopharma

Atkins Announces Partnership with Reality TV Star Heather Gay to Address GLP-1 User’s Mindsets

JP Morgan 2026 Wrap Up: Pharma Leaders Speak About the Conference and the State of the Industry

Henlius Enters Global Exclusive License Agreement with U-mab Biopharma for Best-in-Class Potential Anti-IL-1RAP mAb

Trending on PharmExec

JP Morgan 2026 Wrap Up: Pharma Leaders Speak About the Conference and the State of the Industry

Pharma Companies Raise List Prices, Including 16 That Had Agreements to Lower Prices with Trump Administration: Report

Henlius Enters Global Exclusive License Agreement with U-mab Biopharma for Best-in-Class Potential Anti-IL-1RAP mAb

Pharmaceutical Executive Daily: Henlius' Exclusive License Agreement with U-Mab Biopharma

The Role of Science at the JP Morgan Healthcare Conference